Diametric Capital, LP I Mab Transaction History

Diametric Capital, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$1.21 - $1.9 $28,626 - $44,950	-23,658 Reduced 19.24%	99,295 $188,000
Q3 2023 Nov 14, 2023	BUY	$1.18 - $3.06 $116,496 - $302,101	98,726 Added 407.5%	122,953 $162,000
Q2 2023 Aug 11, 2023	BUY	$2.95 - $3.85 $30,393 - $39,666	10,303 Added 73.99%	24,227 $72,000
Q1 2023 May 11, 2023	SELL	$3.08 - $7.39 $70,938 - $170,206	-23,032 Reduced 62.32%	13,924 $48,000
Q4 2022 Mar 29, 2023	BUY	$3.22 - $4.86 $25,547 - $38,559	7,934 Added 27.34%	36,956 $154,000

Q3 2022 Nov 14, 2022	SELL	$4.01 - $12.34 $3,969 - $12,216	-990 Reduced 3.3%	29,022 $116,000
Q2 2022 Aug 15, 2022	BUY	$8.27 - $18.43 $248,199 - $553,121	30,012 New	30,012 $339,000

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $125M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Diametric Capital, LP with notifications on news.